ContraFect Corp (NASDAQ:CFRX) was the recipient of a large decrease in short interest in August. As of August 31st, there was short interest totalling 347,500 shares, a decrease of 11.5% from the July 31st total of 392,500 shares. Based on an average trading volume of 487,700 shares, the short-interest ratio is currently 0.7 days. Approximately 0.6% of the company’s stock are sold short.

ContraFect stock traded down $0.01 during mid-day trading on Friday, hitting $0.39. The company’s stock had a trading volume of 9,041 shares, compared to its average volume of 449,140. The firm’s 50 day moving average is $0.40 and its 200 day moving average is $0.46. The company has a market cap of $30.97 million, a PE ratio of -1.07 and a beta of 0.15. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.15 and a quick ratio of 4.15. ContraFect has a 52-week low of $0.27 and a 52-week high of $2.63.

Several brokerages recently issued reports on CFRX. ValuEngine raised ContraFect from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Maxim Group began coverage on ContraFect in a research note on Tuesday, June 11th. They issued a “buy” rating for the company.

Institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new stake in ContraFect in the 2nd quarter worth about $343,000. Hartwell J M Limited Partnership lifted its stake in ContraFect by 40.0% in the 2nd quarter. Hartwell J M Limited Partnership now owns 140,000 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 40,000 shares in the last quarter. White Pine Capital LLC lifted its stake in ContraFect by 207.9% in the 1st quarter. White Pine Capital LLC now owns 907,430 shares of the biotechnology company’s stock worth $361,000 after acquiring an additional 612,700 shares in the last quarter. Trellus Management Company LLC acquired a new position in ContraFect in the 2nd quarter worth about $295,000. Finally, Oracle Investment Management Inc. increased its position in ContraFect by 13.1% in the 2nd quarter. Oracle Investment Management Inc. now owns 6,356,649 shares of the biotechnology company’s stock worth $3,242,000 after purchasing an additional 735,450 shares during the last quarter. 34.86% of the stock is owned by hedge funds and other institutional investors.

ContraFect Company Profile

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Recommended Story: How dollar cost averaging works

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.